TANDEM DIABETES CARE INCTNDMEarnings & Financial Report
Tandem Diabetes Care, Inc. is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.
Revenue
$240.7M
Gross Profit
$125.9M
Operating Profit
$-51.8M
Net Profit
$-52.4M
Gross Margin
52.3%
Operating Margin
-21.5%
Net Margin
-21.8%
YoY Growth
8.5%
EPS
$-0.78
TANDEM DIABETES CARE INC Q2 FY2025 Financial Summary
TANDEM DIABETES CARE INC reported revenue of $240.7M (up 8.5% YoY) for Q2 FY2025, with a net profit of $-52.4M (down 70.1% YoY) (-21.8% margin). Cost of goods sold was $114.8M, operating expenses totaled $177.7M.
Key Financial Metrics
| Total Revenue | $240.7M |
|---|---|
| Net Profit | $-52.4M |
| Gross Margin | 52.3% |
| Operating Margin | -21.5% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
TANDEM DIABETES CARE INC Q2 FY2025 revenue of $240.7M breaks down across 2 segments, led by Supplies And Other at $128.8M (53.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Supplies And Other | $128.8M | 53.5% |
| Pump | $111.9M | 46.5% |
TANDEM DIABETES CARE INC Revenue by Segment — Quarterly Trend
TANDEM DIABETES CARE INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Supplies And Other and Pump) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Supplies And Other | — | $150.3M | $139.1M | $128.8M |
| Pump | — | $140.1M | $110.1M | $111.9M |
TANDEM DIABETES CARE INC Annual Revenue by Year
TANDEM DIABETES CARE INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.0B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.0B |
| 2024 | $940.2M |
| 2023 | $747.7M |
| 2022 | $801.2M |
TANDEM DIABETES CARE INC Quarterly Revenue & Net Profit History
TANDEM DIABETES CARE INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $247.2M | +5.5% | $-20.4M | -8.2% |
| Q4 FY2025 | $290.4M | +2.7% | $-589.0K | -0.2% |
| Q3 FY2025 | $249.3M | +2.2% | $-21.2M | -8.5% |
| Q2 FY2025 | $240.7M | +8.5% | $-52.4M | -21.8% |
| Q1 FY2025 | $234.4M | +22.3% | $-130.6M | -55.7% |
| Q4 FY2024 | $282.6M | +43.6% | $755.0K | 0.3% |
| Q3 FY2024 | $244.0M | +31.4% | $-23.3M | -9.5% |
| Q2 FY2024 | $221.9M | +13.3% | $-30.8M | -13.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $221.9M | $244.0M | $282.6M | $234.4M | $240.7M | $249.3M | $290.4M | $247.2M |
| YoY Growth | 13.3% | 31.4% | 43.6% | 22.3% | 8.5% | 2.2% | 2.7% | 5.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $937.5M | $957.7M | $967.7M | $922.1M | $875.7M | $874.7M | $881.1M | $1.15B |
| Liabilities | $703.6M | $720.0M | $704.6M | $766.9M | $742.5M | $741.7M | $725.9M | $1.02B |
| Equity | $233.9M | $237.7M | $263.1M | $155.3M | $133.3M | $133.0M | $155.2M | $132.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-5.3M | $26.8M | $10.7M | $-18.3M | $-9.5M | $8.3M | $9.8M |